多西环素:对阿尔茨海默氏病的重要工具
1Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy.
概括
一种重新使用的抗生素多西环素,通过抑制蛋白质聚合和减少神经炎症,显示出治疗神经退行性疾病的潜力. 其广泛的治疗作用和安全性使其成为精密医学方法的有希望的候选者.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 确定神经退行性疾病的有效治疗方法仍然是一个重大挑战.
- 重用药物为开发新的治疗干预提供了一个有希望的战略.
- 环素,包括多西环素,具有干扰粉样蛋白形成的结构性质.
研究的目的:
- 调查多西环林作为神经退行性疾病治疗剂的潜力.
- 评估多克西环素的抗粉原,抗,抗炎和抗氧化特性.
- 探索准确医学原则在多西环林治疗中的应用.
主要方法:
- 在体外和体内实验来评估抗子活性.
- 临床试验在人类受试者与相关的脑病变.
- 关于多西环素与粉样β,α-synuclein和tau聚合物的相互作用的研究.
- 在实验模型中评估抗炎和抗氧化作用.
主要成果:
- 多西环素显示出破坏或抑制蛋白聚合物形成的能力.
- 在治疗外围粉样性粉症时观察到积极的结果.
- 多西环素与β-粉样蛋白,α-synuclein寡合体和tau聚合物相互作用.
- 发现了抗炎和抗氧化作用,这可能解释了神经炎症模型中的疗效.
结论:
- 多西环素表现出性作用,包括抗氨基原,抗,抗炎和抗氧化作用.
- 它的良好的安全性支持长期治疗,特别是对外围粉样性粉症.
- 多西环林是解决多因子神经退行性疾病中神经元功能障碍的一个有价值的工具.
- 精准医学方法对于优化多西环林的治疗疗效至关重要.
相关概念视频
Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
Alzheimer's Disease: Overview
342
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
342
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
86
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
86
Role of Neurotransmitters in Memory
330
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
330
Dementia
74
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
74
Parkinson's Disease: Treatment
161
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
161


